drugset / Trial / NCT01884597
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
Timeline
- Start
- 2010-11
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 1 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |
Indications
No indication recorded.